Clinical Trials
3 trialsNCT02457598 2025-06-17
Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
Gilead Sciences
Phase 1 Terminated
NCT02457559 2022-03-24
Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies
Gilead Sciences
Phase 1 Completed
NCT01659255 2021-03-16
Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL
Gilead Sciences
Phase 1 Completed